ADHD Treatment for Adults: Medication, Therapy and the Evidence

The best-supported ADHD treatment for adults, judged by randomized trials, is medication: stimulants and the non-stimulant atomoxetine. A 2025 network meta-analysis in The Lancet Psychiatry pooled 113 randomized trials with 14,887 adults, and these were the only treatments that reduced core ADHD symptoms on both self-rated and clinician-rated scales at about 12 weeks^[1].

Cognitive behavioral therapy (CBT), mindfulness and psychoeducation beat placebo only when clinicians rated symptoms, not when adults rated their own^[1]. The same review found that ADHD medications did not improve quality of life and that evidence beyond the short term is underinvestigated^[1].

Guidelines turn this evidence into a sequence. England's National Institute for Health and Care Excellence (NICE) recommends offering medication to adults whose symptoms still cause significant impairment in at least one area of life after environmental modifications have been made and reviewed^[2]. It recommends non-drug treatment for adults who choose not to take medication, have trouble adhering to it, or find it ineffective or intolerable^[2].

U.S. pediatric guidance stops at adulthood: the American Academy of Pediatrics 2019 guideline covers children and adolescents and states that care beyond age 18 was not studied^[6]. In its 2024 report on adult ADHD treatment, CDC wrote that clinical care guidelines for adults could improve standards of care^[3].

How common ADHD is among adults, by age and sex, is tracked on the ADHD in adults page.

Among individual drugs, amphetamines showed the largest effect in adults. A 2018 network meta-analysis that included 8,131 adults in its 12-week efficacy analysis reported clinician-rated effect sizes of -0.79 for amphetamines, -0.49 for methylphenidate, -0.46 for bupropion and -0.45 for atomoxetine, while modafinil did not beat placebo^[7].

Tolerability pointed the other way. Amphetamines, atomoxetine, methylphenidate and modafinil all led to more dropouts because of side effects than placebo in adults^[7]. Weighing both, the authors concluded that the evidence supports amphetamines as the preferred first choice for short-term treatment in adults^[7].

NICE lists lisdexamfetamine or methylphenidate as first-line options and suggests switching to the other after an adequate 6-week trial that brings too little benefit^[2]. Atomoxetine is offered when adults cannot tolerate either drug, or when neither worked in separate 6-week trials^[2]. NICE reserves guanfacine for adults to cases with advice from a tertiary ADHD service^[2].

FDA has approved four non-stimulants for ADHD: atomoxetine (Strattera), guanfacine (Intuniv), clonidine (Kapvay) and viloxazine (Qelbree)^[8]. Brand names, side effects and long-term safety data are compared in ADHD meds.

Yes, though the evidence is weaker than for medication. A 2018 Cochrane review of 14 randomized trials with 700 adults found low-quality evidence that cognitive behavioral treatments may help adults with ADHD in the short term^[4].

Compared with a waiting list, CBT reduced self-reported ADHD symptoms (SMD -0.84, 5 trials, moderate-quality evidence)^[4]. Compared with supportive therapy, CBT did not significantly reduce self-reported symptoms (SMD -0.16)^[4].

CBT also reduced self-reported depression and anxiety compared with a waiting list^[4]. The reviewers cautioned that long-term follow-up was scarce and that 13 of the 14 trials were run in the northern hemisphere^[4].

For adults on a non-drug route, NICE sets a minimum of a structured supportive psychological intervention focused on ADHD plus regular follow-up in person or by phone, which may include parts of or a full course of CBT^[2].

Does adding therapy to medication help?

CBT plus medication outperformed medication alone on clinician-rated core symptoms (SMD -0.80), but that estimate rests on 2 trials with 65 participants and very low-quality evidence^[4]. NICE suggests adding non-drug treatment for adults who benefit from medication yet still have significant impairment^[2].

Session structure and trial details are covered in CBT for ADHD, and the evidence on organizational-skills tools is in ADHD planner.

About a third get none^[3]. In CDC's Rapid Surveys System, fielded in October and November 2023, 36.5% of adults with current ADHD had received no treatment in the past 12 months, and 35.2% had received both medication and counseling or behavioral treatment^[3].

Half (50.4%) had been prescribed ADHD medication in the past year; 33.4% took a stimulant and 5.9% a non-stimulant^[3]. More than half (55.9%) were first diagnosed at age 18 or older^[3].

Supply has been a barrier. Among adults taking a stimulant, 71.5% reported trouble getting a prescription filled because the medication was unavailable^[3].

Telehealth carries a large share of adult care: 46.0% of adults with ADHD had ever used it for ADHD, and 30.5% had used it to get a medication prescription since March 2020^[3]. Federal flexibilities that let DEA-registered practitioners prescribe Schedule II to V controlled medications by telemedicine without a prior in-person evaluation run through December 31, 2026^[9].

The survey relies on self-reported diagnoses and online panels with low response rates, so its estimates may be affected by recall and nonresponse bias^[3].

Before medication starts, NICE recommends recording pulse and blood pressure and doing a cardiovascular assessment; an ECG is not needed unless specific cardiac warning signs are present^[2]. Hypertensive blood pressure, chest pain suggesting a cardiac cause, or sudden death in a first-degree relative under 40 suggesting heart disease warrants a cardiology referral first^[2].

Long-term use carries a cardiovascular signal. A Swedish case-control study of 278,027 people with ADHD aged 6 to 64 found each additional year of medication use was associated with a 4% higher risk of cardiovascular disease, with most of the rise in the first 3 years^[10]. More than 5 years of use was associated with higher odds of hypertension than no use (adjusted odds ratio 1.80), and the pattern held for adults aged 25 and older^[10].

Misuse is the other documented risk. In 2023, FDA required updated Boxed Warnings across all prescription stimulants on misuse, abuse, addiction and overdose, and added that patients should never share their stimulants^[11]. FDA's literature review found that 56% to 80% of people using prescription stimulants nonmedically got them from friends or family^[11].

Where misuse or diversion is a risk, NICE advises against immediate-release stimulants and modified-release forms that are easy to inject or snort^[2]. It also recommends that a clinician with ADHD expertise review medication at least once a year^[2].

Many stop within a year^[5]. A study of 1,229,972 new medication users in eight countries and Hong Kong found that 48% of adults aged 25 and older, and 39% of young adults aged 18 to 24, were still on treatment one year after starting^[5]. At 5 years, 30% to 40% of adults were covered by treatment in most countries once restarts were counted^[5].

NICE suggests considering trial periods of stopping or lowering the dose when the balance of benefits and harms is reassessed^[2].

Real-world studies point to effects beyond symptom scores. In 2,319,450 U.S. patients with ADHD (mean age 32.5), the risk of emergency visits for motor vehicle crashes was 38% lower for men and 42% lower for women in months on medication than in months off it, comparing each person with themselves^[12].

Within-person designs remove stable differences between people but not everything that changes over time, so these findings remain associations. Randomized evidence past about 12 weeks is limited, which the 2025 meta-analysis called underinvestigated^[1].

How treatment differs for children is covered in treating ADHD, and prescriber types and wait times in ADHD psychiatrist.